{"id":139826,"date":"2022-05-26T00:02:18","date_gmt":"2022-05-26T05:02:18","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/05\/a-new-approach-to-therapy-resistant-tumors-targets-a-specific-cell-death-pathway"},"modified":"2022-05-26T00:02:18","modified_gmt":"2022-05-26T05:02:18","slug":"a-new-approach-to-therapy-resistant-tumors-targets-a-specific-cell-death-pathway","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/05\/a-new-approach-to-therapy-resistant-tumors-targets-a-specific-cell-death-pathway","title":{"rendered":"A new approach to therapy-resistant tumors targets a specific cell-death pathway"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/a-new-approach-to-therapy-resistant-tumors-targets-a-specific-cell-death-pathway3.jpg\"><\/a><\/p>\n<p>In a paper appearing in <i>Nature<\/i> today, an international group of scientists report a new way to kill hard-to-treat cancers. These tumors resist current immunotherapies, including those using Nobel Prize-winning checkpoint-blocking antibodies.<\/p>\n<p>The approach exploits Z-DNA. Rather than twisting to the right like B-DNA, Z-DNA has a left-handed twist. One role for Z-DNA is to regulate the <a href=\"https:\/\/medicalxpress.com\/tags\/immune+response\/\" rel=\"tag\" class=\"\">immune response<\/a> to viruses. The response involves AADR1 and ZBP1, two proteins that specifically recognize Z-DNA. They do so through a Z\u03b1 domain that binds to the Z-DNA structure with high affinity.<\/p>\n<p>The Z\u03b1 domain was originally discovered by Dr. Alan Herbert of InsideOutBio, a communicating author on the paper. The ADAR1 Z\u03b1 domain turns off the <a href=\"https:\/\/medicalxpress.com\/tags\/autoimmune+response\/\" rel=\"tag\" class=\"\">autoimmune response<\/a>, while the other ZBP1 Z\u03b1 turns on pathways that kill virally infected <a href=\"https:\/\/medicalxpress.com\/tags\/cells\/\" rel=\"tag\" class=\"\">cells<\/a>, as previously shown by Dr. Sid Balachandran, the other communicating author on the paper. The interactions between ADAR1 and ZBP1 determine whether a <a href=\"https:\/\/medicalxpress.com\/tags\/tumor\/\" rel=\"tag\" class=\"\">tumor<\/a> cell lives or dies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a paper appearing in Nature today, an international group of scientists report a new way to kill hard-to-treat cancers. These tumors resist current immunotherapies, including those using Nobel Prize-winning checkpoint-blocking antibodies. The approach exploits Z-DNA. Rather than twisting to the right like B-DNA, Z-DNA has a left-handed twist. One role for Z-DNA is to [\u2026]<\/p>\n","protected":false},"author":461,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-139826","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/139826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/461"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=139826"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/139826\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=139826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=139826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=139826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}